Palvella Therapeutics, Inc. (PVLA) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases. Palvella Therapeutics is headquartered in Wayne, Pennsylvania.
No case yet. It builds on the next filing, report or 13F period.
Of the 6 companies Palvella Therapeutics, Inc. moves with most closely, none share its SEC classification.
Measured against 415 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
PVLA (Palvella Therapeutics, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
High 154.60 at 5:00 am ET, low 150.74 at 4:00 pm ET.
Palvella Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
197 managers report a position worth $2.2B between them, and 27 of them hold 80% of it.